WO2014049841A1 - マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 - Google Patents
マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 Download PDFInfo
- Publication number
- WO2014049841A1 WO2014049841A1 PCT/JP2012/075119 JP2012075119W WO2014049841A1 WO 2014049841 A1 WO2014049841 A1 WO 2014049841A1 JP 2012075119 W JP2012075119 W JP 2012075119W WO 2014049841 A1 WO2014049841 A1 WO 2014049841A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meibomian gland
- clarithromycin
- therapeutic
- eye
- dysfunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the present invention relates to a therapeutic or prophylactic agent for meibomian gland dysfunction or meibomian gland infarction.
- Meibomian gland dysfunction is a state in which the function of the meibomian gland has been diffusely abnormal due to various causes, and is associated with chronic eye discomfort.
- Meibomian gland infarction refers to a condition in which the function of the meibomian gland is reduced, a white transparent oily mass is formed in the secretory tract, and the meibomian gland is clogged.
- clarithromycin is one of macrolide antibiotics and is used for the treatment of pharyngitis, tonsillitis, pneumonia, skin infection, acute exacerbation of chronic bronchitis and the like based on its antibacterial action.
- clarithromycin is known to have anti-inflammatory action, immunomodulation action, action against bacterial biofilm, etc. in addition to antibacterial action, and based on these new actions, endometriosis or uterine fibroids, gastrointestinal disorders.
- Patent Documents 1, 2, and 3 Patent Documents 1, 2, and 3
- JP 2006-241172 A JP-A-6-92850 JP-A-11-147827
- the inventors of the present invention conducted intensive research in order to search for new pharmaceutical uses of clarithromycin.
- the present invention is a therapeutic or prophylactic agent for meibomian gland dysfunction or meibomian gland infarction containing clarithromycin as an active ingredient.
- a preparation containing clarithromycin as an active ingredient is expected to be effective in treating or preventing meibomian gland dysfunction and meibomian gland infarction.
- the clarithromycin in the present invention can be easily produced by a conventional method, or a commercially available product can be obtained.
- Meibomian gland dysfunction is a state in which the function of the meibomian gland has diffused abnormally due to various causes and is associated with chronic eye discomfort. Meibomian gland dysfunction is classified into a secreted form and an increased secreted form from the state of meibomian gland fat secretion, and the frequency in the secreted form tends to be higher in the decreased secreted form than in the increased secreted form.
- Secretory-reduced meibomian gland dysfunction is a state in which the secretion of meibomian gland fat is reduced due to accumulation of excess keratin in the meibomian gland duct or obstruction of the opening of the meibomian gland caused by various causes.
- characteristic findings of decreased secretion type MGD observation of obstruction of the opening of the meibomian gland and abnormal findings around the opening of the meibomian gland (vasodilation, movement of the mucosal skin transition part, irregular eyelid margin, etc.) are observed.
- Increased secretory meibomian gland dysfunction is a disease characterized by excessive oil secretion from the meibomian gland and a large amount of meibomian gland lipids being squeezed to the margin of the eyelid in response to pressure on the stenosis.
- Meibomian gland infarction is a state in which a mixture of keratin and oil is solidified in the meibomian gland duct, and as a characteristic finding, obstruction of the opening of the meibomian gland is observed.
- Symptoms caused by meibomian gland dysfunction or meibomian gland infarction include various symptoms such as eye discomfort, burning sensation and itching.
- the therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland infarction of the present invention can be administered either orally or parenterally.
- the dosage form include parenteral dosage forms such as eye drops, eye ointments and injections, and oral dosage forms such as tablets, capsules, granules and powders, with eye drops being particularly preferred.
- isotonic agents such as sodium chloride and concentrated glycerin
- buffering agents such as sodium phosphate and sodium acetate, polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil, etc.
- a surfactant can be used as necessary, and stabilizers such as sodium citrate and sodium edetate, and preservatives such as benzalkonium chloride and paraben can be used as necessary.
- the pH may be in the range acceptable for ophthalmic preparations, and is preferably in the range of 4-8.
- an eye ointment In the case of an eye ointment, it can be formulated using a commonly used base such as white petrolatum or liquid paraffin.
- oral preparations such as tablets, capsules, granules and powders
- bulking agents such as lactose, crystalline cellulose, starch and vegetable oil, lubricants such as magnesium stearate and talc, binders such as hydroxypropylcellulose and polyvinylpyrrolidone
- binders such as hydroxypropylcellulose and polyvinylpyrrolidone
- Disintegrating agents such as carboxymethylcellulose / calcium and low-substituted hydroxypropylmethylcellulose, coating agents such as hydroxypropylmethylcellulose, macrogol and silicone resin, and coating agents such as gelatin film, etc. it can.
- the dosage of clarithromycin can be appropriately selected according to symptoms, age, dosage form, etc.
- 0.0001-5% (w / v), preferably 0.01-3% (w / V) may be instilled about 1 to 6 times a day.
- 0.1 to 5000 mg, preferably 1 to 1000 mg of clarithromycin may be administered once or divided into several times per day.
- the present invention includes the following inventions.
- Clarithromycin for use in the treatment or prevention of meibomian gland dysfunction or meibomian gland infarction.
- the clarithromycin according to (1) formulated into an eye drop or eye ointment dosage form.
- the use according to (3), wherein the pharmaceutical dosage form is eye drops or eye ointment.
- Formulation Example 1 1g Clarithromycin in 100ml Concentrated glycerin 2g Sodium hydrogen phosphate hydrate 0.1g Stearate polyoxyl 40 0.1g Dilute hydrochloric acid / sodium hydroxide appropriate amount Sterile purified water appropriate amount pH 7.0
- dissolved eye drops having a concentration of 0.01% (w / v), 0.1% (w / v), and 1.0% (w / v) can be prepared.
- Formulation Example 2 1g Clarithromycin in 100ml Sodium chloride 0.75g Disodium hydrogen phosphate 0.06g Sodium dihydrogen phosphate 0.6g Polysorbate 80 0.005g 0.001 g of hypromellose Edetate sodium hydrate 0.01g Dilute hydrochloric acid / sodium hydroxide appropriate amount Sterile purified water appropriate amount pH 7.0
- suspension type eye drops having a concentration of 0.1% (w / v) and 0.5% (w / v) can be prepared.
- an eye ointment having a concentration of 1% (w / w) and 5% (w / w) can be prepared.
- Peripheral capillary dilatation test by administration of complete Freund's adjuvant in rats (Method for preparing test solution) Clarithromycin (LKT laboratories, Inc.), concentrated glycerin, sodium hydrogenphosphate hydrate and polyoxyl 40 stearate were added to purified water and dissolved to give a final concentration of 1% (w / v) clarithromycin, pH 7 A test solution was prepared.
- the group was divided into a physiological saline administration group and a 1% (w / v) clarithromycin aqueous solution administration group, and each group was tested with 6 eyes so that the variation of the average value of each score was small. Then, physiological saline (5 ⁇ L / eye, 6 times a day) and 1% clarithromycin aqueous solution (5 ⁇ L / eye, 3 times or 6 times a day) were instilled into the right eye for 21 days. On the 28th day after induction, the periphery of the meibomian gland opening in the upper right eyelid was observed using a slit lamp, and score determination was performed.
- Table 2 shows the results (average value of capillary dilation score).
- Table 3 shows the results (average value of the number of closed openings).
- clarithromycin as an active ingredient, it is possible to treat or prevent meibomian gland dysfunction and meibomian gland infarction.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(1) マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防に用いられるためのクラリスロマイシン。
(2) 点眼剤または眼軟膏の剤型に製剤化される(1)記載のクラリスロマイシン。
(3) マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防用医薬品の製造における、クラリスロマイシンの使用。
(4) 前記医薬品の剤型が、点眼剤または眼軟膏である(3)記載の使用。
100ml中
クラリスロマイシン 1g
濃グリセリン 2g
リン酸水素ナトリウム水和物 0.1g
ステアリン酸ポリオキシル40 0.1g
希塩酸/水酸化ナトリウム 適量
滅菌精製水 適量
pH 7.0
100ml中
クラリスロマイシン 1g
塩化ナトリウム 0.75g
リン酸水素二ナトリウム 0.06g
リン酸二水素ナトリウム 0.6g
ポリソルベート80 0.005g
ヒプロメロース 0.001g
エデト酸ナトリウム水和物 0.01g
希塩酸/水酸化ナトリウム 適量
滅菌精製水 適量
pH 7.0
100ml中
クラリスロマイシン 2g
流動パラフィン 30g
白色ワセリン 適量
1.ラットを用いた完全フロイントアジュバントの投与によるマイボーム腺周辺毛細血管拡張試験
(被験液調製方法)
クラリスロマイシン(LKT laboratories, Inc.)、濃グリセリン、リン酸水素ナトリウム水和物およびステアリン酸ポリオキシル40を精製水に加えて溶解させ、クラリスロマイシン最終濃度1%(w/v)、pH7の被験液を調製した。
5週齢の雌性Lewisラットに完全フロイントアジュバント25μLを右上眼瞼に1箇所投与した。惹起7日目に、スリットランプを用いて右上眼瞼のマイボーム腺開口部周辺を観察し、毛細血管拡張スコア判定を行った。表1の基準に従って、上眼瞼の眼瞼縁を耳側、中央部、鼻側の3分画に等分し、それぞれの分画についてマイボーム腺開口部周辺の毛細血管拡張スコアを判定し、3分画のスコアの和を1眼あたりのスコアとして算出した。なお、毛細血管の拡張の有無は、血管径が拡大した結果、通常視認できない毛細血管が確認できる状態にあるか否かで判定した。
結果(毛細血管拡張スコアの平均値)を表2に示す。
惹起7日目(投与開始0日目)では、各群の毛細血管拡張スコアの平均値に差は認められなかったが、惹起後28日目(投与開始21日目)では、1%(w/v)クラリスロマイシン水溶液投与群(1日3回点眼または6回点眼)は生理食塩液投与群に比べ、マイボーム腺開口部付近の毛細血管拡張スコアを顕著に低下させた。
(被験液調製方法)
薬理試験1と同様の操作をして、1%(w/v)クラリスロマイシン被験液を調製した。
5週齢の雄性Hos:HR-1系ヘアレスマウスを、通常飼料給餌群6匹(CRF-1飼料、オリエンタル酵母工業株式会社製)、HR-AD飼料給餌群12匹(日本農産工業株式会社製)に群分けし、それぞれに通常飼料またはHR-AD飼料を給餌し、自発的に摂取させた。給餌開始後28日目に、スリットランプを用いて、マイボーム腺開口部を観察し、上眼瞼の中央8個のマイボーム腺開口部の中で、閉塞している開口部の数を計測した。なお、マイボーム腺開口部の閉塞の有無は、マイボーム腺開口部が白濁して盛り上がった状態にあるか否かで判定した。
結果(開口部閉塞数の平均値)を表3に示す。
給餌開始28日目(投与開始0日目)では、生理食塩液投与群(HR-AD飼料給餌)と1%(w/v)クラリスロマイシン水溶液投与群(HR-AD飼料給餌)のマイボーム腺開口部の閉塞数の間に差がほとんどなかったが、給餌開始後42日目(投与開始14日目)では、1%(w/v)クラリスロマイシン水溶液投与群は、マイボーム腺開口部の閉塞数を顕著に減少させ、マイボーム腺梗塞を改善した。
Claims (4)
- クラリスロマイシンを有効成分として含有するマイボーム腺機能不全またはマイボーム腺梗塞の治療剤または予防剤。
- マイボーム腺機能不全の治療剤または予防剤である請求項1記載の治療剤または予防剤。
- マイボーム腺梗塞の治療剤または予防剤である請求項1記載の治療剤または予防剤。
- 剤型が、点眼剤または眼軟膏である請求項1~3いずれか記載の治療剤または予防剤。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280074718.4A CN104470513B (zh) | 2012-09-28 | 2012-09-28 | 睑板腺功能障碍或睑板腺堵塞的治疗或预防剂 |
KR1020157003637A KR20150031471A (ko) | 2012-09-28 | 2012-09-28 | 마이봄샘 기능 부전 또는 마이봄샘 경색의 치료제 또는 예방제 |
KR1020167006025A KR20160032260A (ko) | 2012-09-28 | 2012-09-28 | 마이봄샘 기능 부전 또는 마이봄샘 경색의 치료제 또는 예방제 |
PCT/JP2012/075119 WO2014049841A1 (ja) | 2012-09-28 | 2012-09-28 | マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 |
EP12885416.3A EP2902023A4 (en) | 2012-09-28 | 2012-09-28 | THERAPEUTIC OR PROPHYLACTIC FOR MEXOM PRUNE DYNAMIC FUNCTION OR MOMENTARY DRUG BLOCKING |
RU2015108281/15A RU2586289C1 (ru) | 2012-09-28 | 2012-09-28 | Терапевтический или профилактический агент от дисфункции мейбомиевых желез или блокады мейбомиевых желез |
US14/670,999 US9539204B2 (en) | 2012-09-28 | 2012-09-28 | Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage |
CA2886042A CA2886042C (en) | 2012-09-28 | 2012-09-28 | Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage |
US15/363,583 US9999594B2 (en) | 2012-09-28 | 2016-11-29 | Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2012/075119 WO2014049841A1 (ja) | 2012-09-28 | 2012-09-28 | マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/670,999 A-371-Of-International US9539204B2 (en) | 2012-09-28 | 2012-09-28 | Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage |
US15/363,583 Continuation US9999594B2 (en) | 2012-09-28 | 2016-11-29 | Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014049841A1 true WO2014049841A1 (ja) | 2014-04-03 |
Family
ID=50387302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/075119 WO2014049841A1 (ja) | 2012-09-28 | 2012-09-28 | マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US9539204B2 (ja) |
EP (1) | EP2902023A4 (ja) |
KR (2) | KR20150031471A (ja) |
CN (1) | CN104470513B (ja) |
CA (1) | CA2886042C (ja) |
RU (1) | RU2586289C1 (ja) |
WO (1) | WO2014049841A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8915253B2 (en) | 2005-07-18 | 2014-12-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US9216028B2 (en) | 2005-07-18 | 2015-12-22 | Tearscience, Inc. | Apparatuses for treatment of meibomian glands |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
US9719977B2 (en) | 2005-07-18 | 2017-08-01 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US9913678B2 (en) | 2005-07-18 | 2018-03-13 | Tearscience, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
US10940074B2 (en) | 2005-07-18 | 2021-03-09 | Tearscience Inc | Melting meibomian gland obstructions |
US10952896B2 (en) | 2006-05-15 | 2021-03-23 | Tearscience Inc | Methods and apparatuses for treatment of meibomian gland dysfunction |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2862439A4 (en) * | 2012-06-19 | 2016-04-13 | Santen Pharmaceutical Co Ltd | METHOD FOR MODIFYING THE STATUS OF ANIMALS WITHOUT HAIR |
EP2863219A4 (en) * | 2012-06-19 | 2016-04-20 | Santen Pharmaceutical Co Ltd | METHOD FOR CHANGING AN EYELID STATUS BY ADMINISTERING THE COMPLETE FRIENDS ADJUVANS |
WO2014049841A1 (ja) * | 2012-09-28 | 2014-04-03 | 参天製薬株式会社 | マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 |
KR101714710B1 (ko) | 2015-09-17 | 2017-03-10 | 고려대학교 산학협력단 | 마이봄샘 압출기 |
WO2021191273A1 (en) | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
WO2022109497A1 (en) | 2020-11-23 | 2022-05-27 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0692850A (ja) | 1991-09-20 | 1994-04-05 | Glaxo Group Ltd | 胃腸障害治療薬 |
JPH11147827A (ja) | 1997-11-19 | 1999-06-02 | Eisai Co Ltd | 抗そう痒剤 |
JP2006241172A (ja) | 2000-11-15 | 2006-09-14 | Masao Sugamata | 子宮内膜症の予防又は治療薬 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU0104790D0 (en) | 2001-11-08 | 2002-01-28 | Human Rt | Pharmaceutical combinations for topical application |
CN1452977A (zh) * | 2003-05-20 | 2003-11-05 | 广州贝氏药业有限公司 | 一种克拉霉素注射剂 |
CN1475220A (zh) * | 2003-06-24 | 2004-02-18 | 广州贝氏药业有限公司 | 一种克拉霉素药物制剂 |
CN1850045A (zh) * | 2006-05-22 | 2006-10-25 | 济南康泉医药科技有限公司 | 一种含大环内酯抗生素的缓释制剂 |
US9328162B2 (en) * | 2010-02-25 | 2016-05-03 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
WO2014049841A1 (ja) * | 2012-09-28 | 2014-04-03 | 参天製薬株式会社 | マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 |
-
2012
- 2012-09-28 WO PCT/JP2012/075119 patent/WO2014049841A1/ja active Application Filing
- 2012-09-28 KR KR1020157003637A patent/KR20150031471A/ko active Application Filing
- 2012-09-28 KR KR1020167006025A patent/KR20160032260A/ko active IP Right Grant
- 2012-09-28 US US14/670,999 patent/US9539204B2/en not_active Expired - Fee Related
- 2012-09-28 CA CA2886042A patent/CA2886042C/en not_active Expired - Fee Related
- 2012-09-28 EP EP12885416.3A patent/EP2902023A4/en not_active Withdrawn
- 2012-09-28 RU RU2015108281/15A patent/RU2586289C1/ru not_active IP Right Cessation
- 2012-09-28 CN CN201280074718.4A patent/CN104470513B/zh not_active Expired - Fee Related
-
2016
- 2016-11-29 US US15/363,583 patent/US9999594B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0692850A (ja) | 1991-09-20 | 1994-04-05 | Glaxo Group Ltd | 胃腸障害治療薬 |
JPH11147827A (ja) | 1997-11-19 | 1999-06-02 | Eisai Co Ltd | 抗そう痒剤 |
JP2006241172A (ja) | 2000-11-15 | 2006-09-14 | Masao Sugamata | 子宮内膜症の予防又は治療薬 |
Non-Patent Citations (9)
Title |
---|
BERGFELD,W.F.: "A lifetime of healthy skin: implications for women", INT J FERTIL WOMENS MED, vol. 44, no. 2, 1999, pages 83 - 95 * |
DATABASE DATABASE 6 November 2012 (2012-11-06), retrieved from STN Database accession no. 1999268588 * |
HATANO,H. ET AL.: "TE-031 (A-56268) in ophthalmology", CHEMOTHERAPY, vol. 36, 1988, pages 1101 - 1108, XP055249212 * |
KINOSHITA,S.D.: "Paradigm shift in therapeutic modalities for devastating ocular surface disorders", CORNEA, vol. 28, 2009, pages S3 - S6, XP008178970 * |
MAKIKO TAKAGI ET AL.: "Meibom-sen'en Kakumaku Johisho no Chiryo", JAPANESE REVIEW OF CLINICAL OPHTHALMOLOGY, vol. 99, no. 6, 2005, pages 514, XP008178975 * |
NORIHIKO YOKOI ET AL.: "Meibom-senen Kakumaku Johisho ni Taisuru Macrolide Shoryo Choki Ryoho", JAPANESE REVIEW OF CLINICAL OPHTHALMOLOGY, vol. 99, no. 8, 2005, pages 682, XP008178974 * |
NORIHIKO YOKOI: "Meibom-sen ni Kanren shita Gan Hyomen Shikkan", JAPAN MEDICAL JOURNAL, vol. 4166, 2004, pages 33 - 36, XP008178973 * |
SHIRO AMANO ET AL.: "Definition and Diagnostic Criteria for Meibomian Gland Dysfunction", JOURNAL OF THE EYE, vol. 27, no. 5, 2010, pages 627 - 631, XP008175254 * |
TOMO SUZUKI: "Gan Kansensho no Nazo o Toku II. Gan Kansensho Jiten 1. Ganken'en 3) Meibom- sen'en to Kanren Kakumaku Johi Shogai", PRACTICAL OPHTHALMOLOGY, vol. 28, 2009, pages 72 - 73, XP008178972 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8915253B2 (en) | 2005-07-18 | 2014-12-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
US9060843B2 (en) | 2005-07-18 | 2015-06-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
US9216028B2 (en) | 2005-07-18 | 2015-12-22 | Tearscience, Inc. | Apparatuses for treatment of meibomian glands |
US9719977B2 (en) | 2005-07-18 | 2017-08-01 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US9913678B2 (en) | 2005-07-18 | 2018-03-13 | Tearscience, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US10376273B2 (en) | 2005-07-18 | 2019-08-13 | Tearscience, Inc. | Methods and apparatuses for treatment of meibomian glands |
US10905898B2 (en) | 2005-07-18 | 2021-02-02 | Tearscience, Inc. | Methods and apparatuses for treating gland dysfunction |
US10940074B2 (en) | 2005-07-18 | 2021-03-09 | Tearscience Inc | Melting meibomian gland obstructions |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
US10952896B2 (en) | 2006-05-15 | 2021-03-23 | Tearscience Inc | Methods and apparatuses for treatment of meibomian gland dysfunction |
US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
Also Published As
Publication number | Publication date |
---|---|
CN104470513B (zh) | 2015-12-23 |
CN104470513A (zh) | 2015-03-25 |
EP2902023A4 (en) | 2016-03-30 |
US9539204B2 (en) | 2017-01-10 |
CA2886042C (en) | 2015-11-24 |
KR20160032260A (ko) | 2016-03-23 |
EP2902023A1 (en) | 2015-08-05 |
RU2586289C1 (ru) | 2016-06-10 |
US9999594B2 (en) | 2018-06-19 |
US20150245994A1 (en) | 2015-09-03 |
US20170071852A1 (en) | 2017-03-16 |
KR20150031471A (ko) | 2015-03-24 |
CA2886042A1 (en) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014049841A1 (ja) | マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 | |
CN108884053B (zh) | 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法 | |
JP7082162B2 (ja) | マイボーム機能不全の治療剤 | |
WO2014206310A1 (zh) | 一种中药制剂在制备预防和/或治疗克罗恩病的药物中的用途 | |
JP5373167B1 (ja) | マイボーム腺機能不全またはマイボーム腺梗塞の治療または予防剤 | |
JPH01265028A (ja) | 特発性血小板減少性紫斑病治療剤 | |
IE851848L (en) | Propiophenone compound against sexual dysfunction | |
WO2021161983A1 (en) | Novel medicament for treating inflammatory disease | |
US20190336512A1 (en) | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders | |
CN112472718B (zh) | 改善口服清肠或肠道准备剂电解质紊乱副作用的组合物 | |
EP3664786B1 (en) | Method for treating schnitzler's syndrome | |
US11998562B2 (en) | Ophthalmological formulations for the prevention of a coronavirus infection | |
BR102022002332A2 (pt) | Método para o tratamento de infecções por covid-19 com palmitoiletanolamida | |
CN113398109A (zh) | 一种预防或治疗炎性肠病的酮体混合物及其应用 | |
JP3627801B2 (ja) | 副鼻腔炎の予防および/または治療剤 | |
CN115607673A (zh) | 一种治疗睑板腺功能障碍的药物组合物 | |
US20240207338A1 (en) | Ketamine and cannabis for the treatment of emotional disorders | |
WO2022232693A1 (en) | Ketamine and cannabis for the treatment of emotional disorders | |
JP2005035995A (ja) | イブプロフェン含有経口用組成物 | |
JP2011052023A (ja) | イブプロフェン含有経口用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12885416 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20157003637 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2886042 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14670999 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012885416 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015108281 Country of ref document: RU Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: JP |